论文部分内容阅读
目的：观察抗肿瘤新药去甲长春花碱(Navelbine，NVB）为主的联合方案化疗治疗蒽环类耐药的晚期乳腺癌的疗效。方法：1995年9月～1999年2月，以此法治疗晚期乳腺癌21例，其中，NVB＋ADM治疗9例，NVB＋DDP治疗8例，NVB＋MIT 4例。全组化疗共54周期，中位数3周期(2～4周期）。结果：CR 2例，PR 8例，SD 8例，PD 3例，总有效率(CR＋PR）47．6％。全组中位缓解期5个月(2～17个月）。主要剂量限制毒性为骨髓抑制，以白细胞减少为主，Ⅱ～Ⅲ度白细胞减少发生率为90．5％。静脉炎发生率为14．3％(3／21）。结论：以NVB为主的联合化疗对蒽环类药物耐药的转移性乳腺癌有较好的疗效，且毒性可以耐受，可以考虑作为后续化疗方案。
OBJECTIVE: To observe the efficacy of combined anti-tumor drug Navelbine (NVB)-based chemotherapy for the treatment of anthracycline-resistant advanced breast cancer. Methods: From September 1995 to February 1999, 21 cases of advanced breast cancer were treated by this method. Among them, 9 cases were treated with NVB+ADM, 8 cases were treated with NVB+DDP, and 4 cases were NVB+MIT. There were 54 cycles of chemotherapy in the whole group, with a median of 3 cycles (2 to 4 cycles). Results: There were 2 cases of CR, 8 cases of PR, 8 cases of SD, and 3 cases of PD. The total effective rate (CR+PR) was 47.6%. The median remission period of the whole group was 5 months (2 to 17 months). The main dose-limiting toxicity was myelosuppression, with neutropenia predominant, and the incidence of II-III degree leukopenia was 90.5%. The incidence of phlebitis was 14.3% (3/21). Conclusion: NVB-based combination chemotherapy is effective for anthracycline-resistant metastatic breast cancer, and the toxicity can be tolerated. It can be considered as a follow-up chemotherapy regimen.